Tafenoquine (Krintafel) is the first new drug to be approved for the treatment of relapsing Plasmodium vivax malaria in 70 years. Tafenoquine was engineered to be a metabolically stable and thus slowly eliminated version of the 8-aminoquinoline, primaquine, providing relapse prevention with a single dose as compared to 1–2 weeks of daily primaquine. Although it also causes protracted haemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency, it has the potential to accelerate P vivax elimination.
No takes yet. Share an insight, caveat, or question.
Watson et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: